Drug profile · INN
esketamine
SPRAVATO
esketamine (SPRAVATO) is a glutamate [nmda] receptor negative allosteric modulator. Associated with Janssen-Cilag Pty Ltd.
EMA: approved TGA: approved NMPA: clinical trials Nervous system (N06) N06AX27
Patents linked 0
Pipeline programs 23
News articles 1
Drug details — esketamine
- Class
- Nervous system (N06)
- Route
- —
- Patents
- 0
- Programs
- 23
- Data quality
- 0.83
Quick answer
esketamine (SPRAVATO) is a glutamate [nmda] receptor negative allosteric modulator. Associated with Janssen-Cilag Pty Ltd.
Key facts
INN esketamine
Brand SPRAVATO
Mechanism Glutamate [NMDA] receptor negative allosteric modulator
Target Glutamate [NMDA] receptor
Therapeutic class Nervous system (N06)
ATC code N06AX27
Originator Janssen-Cilag Pty Ltd
Mechanism of action
Glutamate [NMDA] receptor negative allosteric modulator
Primary target: Glutamate [NMDA] receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is esketamine?
esketamine (SPRAVATO) is a glutamate [nmda] receptor negative allosteric modulator. Associated with Janssen-Cilag Pty Ltd.
What is the brand name for esketamine?
SPRAVATO is a marketed brand name for esketamine. Check FDA Drugs@FDA for the current US label holder and prescribing information.